Search

Your search keyword '"Griseri, Guido"' showing total 35 results
Start Over Author "Griseri, Guido"
35 results on '"Griseri, Guido"'

1. Factors affecting overall survival and disease-free survival after surgery for hepatocellular carcinoma: a nomogram-based prognostic model—a Western European multicenter study

Author

Masuda, Yoshio, Yeo, Mark Hao Xuan, Burdio, Fernando, Sanchez-Velazquez, Patricia, Perez-Xaus, Marc, Pelegrina, Amalia, Koh, Ye Xin, Di Martino, Marcello, Goh, Brian K.P., Tan, Ek Khoon, Teo, Jin Yao, Romano, Fabrizio, Famularo, Simone, Ferrari, Cecilia, Griseri, Guido, Piardi, Tullio, Sommacale, Daniele, Gianotti, Luca, Molfino, Sarah, Baiocchi, Gianluca, and Ielpo, Benedetto

Published
2024
Full Text
View/download PDF

2. Survival benefit of second line therapies for recurrent hepatocellular carcinoma: repeated hepatectomy, thermoablation and second-line transplant referral in a real life national scenario

Author

Milana, Flavio, Bertacco, Alessandra, De Carlis, Riccardo, Ratti, Francesca, Russolillo, Nadia, Iaria, Maurizio, Razionale, Francesco, Tartaglia, Giuseppe, Ciulli, Cristina, Carissimi, Francesca, Laureiro, Zoe L., Marinelli, Laura, DePeppo, Valerio, Montuori, Mauro, Marchitelli, Ivan, Franceschi, Angelo, Notte, Francesca, Manzoni, Alberto, Cosola, Davide, Corleone, Pio, Fumagalli, Luca, Salvador, Luca, Mantovani, Guido, Cucchetti, Alessandro, Cammarata, Francesco, Conticchio, Maria, Patrone, Renato, Bernasconi, Davide P., Famularo, Simone, Cillo, Umberto, Lauterio, Andrea, Donadon, Matteo, Vitale, Alessandro, Serenari, Matteo, Cipriani, Federica, Fazio, Federico, Giuffrida, Mario, Ardito, Francesco, Dominioni, Tommaso, Garancini, Mattia, Lai, Quirino, Nicolini, Daniele, Molfino, Sarah, Perri, Pasquale, Pinotti, Enrico, Conci, Simone, Ferrari, Cecilia, Zanello, Matteo, Patauner, Stefan, Zimmitti, Giuseppe, Germani, Paola, Chiarelli, Marco, Romano, Maurizio, De Angelis, Michela, La Barba, Giuliano, Troci, Albert, Ferraro, Valentina, Izzo, Francesco, Antonucci, Adelmo, Belli, Andrea, Memeo, Riccardo, Crespi, Michele, Ercolani, Giorgio, Boccia, Luigi, Zanus, Giacomo, Tarchi, Paola, Hilal, Moh'd Abu, Frena, Antonio, Jovine, Elio, Griseri, Guido, Ruzzenente, Andrea, Zago, Mauro, Grazi, Gianluca, Baiocchi, Gian L., Vivarelli, Marco, Rossi, Massimo, Romano, Fabrizio, Maestri, Marcello, Giuliante, Felice, Valle, Raffaele D., Ferrero, Alessandro, Aldrighetti, Luca, De Carlis, Luciano, Cescon, Matteo, and Torzilli, Guido

Published
2023
Full Text
View/download PDF

3. The largest western experience on salvage hepatectomy for recurrent hepatocellular carcinoma: propensity score-matched analysis on behalf of He.RC.O.Le.Study Group

Author

Giuffrida, Mario, Russolillo, Nadia, Razionale, Francesco, De Peppo, Valerio, Tomasoni, Matteo, Marchitelli, Ivan, Costa, Guido, Laureiro, Zoe L., Scotti, Mauro, Calcagno, Pietro, Cosola, Davide, Franceschi, Angelo, Manzoni, Alberto, Pennacchi, Luca, Montuori, Mauro, Conticchio, Maria, Ratti, Francesca, Notte, Francesca, Cucchetti, Alessandro, Salvador, Luca, Corleone, Pio, Garancini, Mattia, Ciulli, Cristina, Iaria, Maurizio, Bianchi, Giorgio, Fazio, Federico, Ardito, Francesco, Perri, Pasquale, Pontarolo, Nicholas, Conci, Simone, Donadon, Matteo, Zanello, Matteo, Lai, Quirino, Famularo, Simone, Molfino, Sarah, Sciannamea, Ivano, Fumagalli, Luca, Germani, Paola, Floridi, Antonio, Ferrari, Cecilia, Zimmitti, Giuseppe, Troci, Albert, Zago, Mauro, Ferraro, Valentina, Cipriani, Federica, Patauner, Stefan, La Barba, Giuliano, Romano, Maurizio, Zanus, Giacomo, Ercolani, Giorgio, Frena, Antonio, Aldrighetti, Luca, Memeo, Riccardo, Pinotti, Enrico, Crespi, Michele, Hilal, Moh'd Abu, Griseri, Guido, Tarchi, Paola, Chiarelli, Marco, Antonucci, Adelmo, Baiocchi, Gian L., Romano, Fabrizio, Rossi, Massimo, Jovine, Elio, Torzilli, Guido, Ruzzenente, Andrea, Maestri, Marcello, Grazi, Gian L., Giuliante, Felice, Ferrero, Alessandro, and Dalla Valle, Raffaele

Published
2022
Full Text
View/download PDF

4. The Effect of a Liver Transplant Program on the Outcomes of Resectable Hepatocellular Carcinoma: A Nationwide Multicenter Analysis

Author

Serenari, Matteo, Lenzi, Jacopo, Cucchetti, Alessandro, Cipriani, Federica, Donadon, Matteo, Ardito, Francesco, Fazio, Federico, Nicolini, Daniele, Iaria, Maurizio, Famularo, Simone, Perri, Pasquale, Ansaloni, Luca, Zanello, Matteo, Lai, Quirino, Conci, Simone, Molfino, Sarah, Ferrari, Cecilia, Germani, Paola, Zago, Mauro, Romano, Maurizio, Zimmitti, Giuseppe, Antonucci, Adelmo, Fumagalli, Luca, Troci, Albert, Ferraro, Valentina, Memeo, Riccardo, Crespi, Michele, Chiarelli, Marco, Ercolani, Giorgio, Hilal, Mohamed A., Zanus, Giacomo, Pinotti, Enrico, Tarchi, Paola, Griseri, Guido, Baiocchi, Gian Luca, Ruzzenente, Andrea, Rossi, Massimo, Jovine, Elio, Maestri, Marcello, Grazi, Gian Luca, Romano, Fabrizio, Dalla Valle, Raffaele, Ravaioli, Matteo, Vivarelli, Marco, Ferrero, Alessandro, Giuliante, Felice, Torzilli, Guido, Aldrighetti, Luca, Cescon, Matteo, Gorgone, Mara, Ratti, Francesca, Costa, Guido, Razionale, Francesco, Russolillo, Nadia, Marinelli, Laura, Giuffrida, Mario, Scotti, Mauro, Garancini, Mattia, De Peppo, Valerio, De Stefano, Francesca, Laureiro, Zoe Larghi, Marchitelli, Ivan, Franceschi, Angelo, Cosola, Davide, Corleone, Pio, Montuori, Mauro, Salvador, Luca, Manzoni, Alberto, La Barba, Giuliano, Calcagno, Pietro, Pennacchi, Luca, and Conticchio, Maria

Published
2023
Full Text
View/download PDF

5. Hepatectomy for Metabolic Associated Fatty Liver Disease (MAFLD) related HCC: Propensity case-matched analysis with viral- and alcohol-related HCC

Author

Conci, Simone, Cipriani, Federica, Donadon, Matteo, Marchitelli, Ivan, Ardito, Francesco, Famularo, Simone, Perri, Pasquale, Iaria, Maurizio, Ansaloni, Luca, Zanello, Matteo, La Barba, Giuliano, Patauner, Stefan, Pinotti, Enrico, Molfino, Sarah, Germani, Paola, Romano, Maurizio, Sciannamea, Ivano, Ferrari, Cecilia, Manzoni, Alberto, Troci, Albert, Fumagalli, Luca, Delvecchio, Antonella, Floridi, Antonio, Memeo, Riccardo, Chiarelli, Marco, Crespi, Michele, Zimmitti, Giuseppe, Griseri, Guido, Antonucci, Adelmo, Zanus, Giacomo, Tarchi, Paola, Baiocchi, Gian Luca, Zago, Mauro, Frena, Antonio, Ercolani, Giorgio, Jovine, Elio, Maestri, Marcello, Valle, Raffaele Dalla, Grazi, Gian Luca, Romano, Fabrizio, Giuliante, Felice, Torzilli, Guido, Aldrighetti, Luca, and Ruzzenente, Andrea

Published
2022
Full Text
View/download PDF

6. Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison

Author

Ciulli, Cristina, Giani, Alessandro, Carissimi, Francesca, Costa, Guido, Ratti, Francesca, Cucchetti, Alessandro, Calabrese, Francesco, Cremaschi, Elena, Lazzari, Giovanni, Franceschi, Angelo, Sega, Valentina, Conticchio, Maria, Pennacchi, Luca, Ciola, Michele, Sciannamea, Ivano, De Peppo, Valerio, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Bernasconi, Davide P., LaBarba, Giuliano, Dominioni, Tommaso, Iaria, Maurizio, Molfino, Sarah, Conci, Simone, Ferrari, Cecilia, Garatti, Marco, Delvecchio, Antonella, Troci, Albert, Patauner, Stefan, Frassani, Silvia, Cosimelli, Maurizio, Zanus, Giacomo, Giuliante, Felice, Jovine, Elio, Valsecchi, Maria G., Grazi, GianLuca, Antonucci, Adelmo, Frena, Antonio, Crespi, Michele, Memeo, Riccardo, Zimmitti, Giuseppe, Griseri, Guido, Ruzzenente, Andrea, Baiocchi, Gianluca, DallaValle, Raffaele, Maestri, Marcello, Ercolani, Giorgio, Aldrighetti, Luca, Torzilli, Guido, and Romano, Fabrizio

Published
2021
Full Text
View/download PDF

7. Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma

Author

Vitale, Alessandro, Romano, Pierluigi, Cillo, Umberto, Lauterio, Andrea, Sangiovanni, Angelo, Cabibbo, Giuseppe, Missale, Gabriele, Marseglia, Mariarosaria, Trevisani, Franco, Foschi, Francesco Giuseppe, Cipriani, Federica, Famularo, Simone, Marra, Fabio, Saitta, Carlo, Serenari, Matteo, Vidili, Gianpaolo, Morisco, Filomena, Caturelli, Eugenio, Mega, Andrea, Pelizzaro, Filippo, Nicolini, Daniele, Ardito, Francesco, Garancini, Mattia, Masotto, Alberto, Baroni, Gianluca Svegliati, Azzaroli, Francesco, Giannini, Edoardo, Perri, Pasquale, Scarinci, Andrea, Fontana, Andrea Pierluigi, Brunetto, Maurizia Rossana, Iaria, Maurizio, Di Marco, Maria, Nardone, Gerardo, Dominioni, Tommaso, Lai, Quirino, Ferrari, Cecilia, Rapaccini, Gian Ludovico, Rodolfo, Sacco, Romano, Maurizio, Conci, Simone, Zoli, Marco, Conticchio, Maria, Zanello, Matteo, Zimmitti, Giuseppe, Fumagalli, Luca, Troci, Albert, Germani, Paola, Gasbarrini, Antonio, La Barba, Giuliano, De Angelis, Michela, Patauner, Stefan, Molfino, Sarah, Zago, Mauro, Pinotti, Enrico, Frigo, Anna Chiara, Baiocchi, Gian Luca, Frena, Antonio, Boccia, Luigi, Ercolani, Giorgio, Tarchi, Paola, Crespi, Michele, Chiarelli, Marco, Abu Hilal, Moh’d, Cescon, Matteo, Memeo, Riccardo, Ruzzenente, Andrea, Zanus, Giacomo, Griseri, Guido, Rossi, Massimo, Maestri, Marcello, Della Valle, Raffaele, Ferrero, Alessandro, Grazi, Gian Luca, Romano, Fabrizio, Giuliante, Felice, Vivarelli, Marco, Jovine, Elio, Torzilli, Guido, Aldrighetti, Luca, and De Carlis, Luciano

Abstract

IMPORTANCE: The 2022 Barcelona Clinic Liver Cancer algorithm currently discourages liver resection (LR) for patients with multinodular hepatocellular carcinoma (HCC) presenting with 2 or 3 nodules that are each 3 cm or smaller. OBJECTIVE: To compare the efficacy of liver resection (LR), percutaneous radiofrequency ablation (PRFA), and transarterial chemoembolization (TACE) in patients with multinodular HCC. DESIGN, SETTING, AND PARTICIPANTS: This cohort study is a retrospective analysis conducted using data from the HE.RC.O.LE.S register (n = 5331) for LR patients and the ITA.LI.CA database (n = 7056) for PRFA and TACE patients. A matching-adjusted indirect comparison (MAIC) method was applied to balance data and potential confounding factors between the 3 groups. Included were patients from multiple centers from 2008 to 2020; data were analyzed from January to December 2023. INTERVENTIONS: LR, PRFA, or TACE. MAIN OUTCOMES AND MEASURES: Survival rates at 1, 3, and 5 years were calculated. Cox MAIC-weighted multivariable analysis and competing risk analysis were used to assess outcomes. RESULTS: A total of 720 patients with early multinodular HCC were included, 543 males (75.4%), 177 females (24.6%), and 350 individuals older than 70 years (48.6%). There were 296 patients in the LR group, 240 who underwent PRFA, and 184 who underwent TACE. After MAIC, LR exhibited 1-, 3-, and 5-year survival rates of 89.11%, 70.98%, and 56.44%, respectively. PRFA showed rates of 94.01%, 65.20%, and 39.93%, while TACE displayed rates of 90.88%, 48.95%, and 29.24%. Multivariable Cox survival analysis in the weighted population showed a survival benefit over alternative treatments (PRFA vs LR: hazard ratio [HR], 1.41; 95% CI, 1.07-1.86; P = .01; TACE vs LR: HR, 1.86; 95% CI, 1.29-2.68; P = .001). Competing risk analysis confirmed a lower risk of cancer-related death in LR compared with PRFA and TACE. CONCLUSIONS AND RELEVANCE: For patients with early multinodular HCC who are ineligible for transplant, LR should be prioritized as the primary therapeutic option, followed by PRFA and TACE when LR is not feasible. These findings provide valuable insights for clinical decision-making in this patient population.

Published
2024
Full Text
View/download PDF

8. Factors Affecting Local and Intra Hepatic Distant Recurrence After Surgery for Hcc: An Alternative Perspective on Microvascular Invasion and Satellitosis – A Western European Multicentre Study

Author

Famularo, Simone, Piardi, Tullio, Molfino, Sarah, Di Martino, Marcello, Ferrari, Cecilia, Ielpo, Benedetto, Diago, Maria Victoria, Giani, Alessandro, Griseri, Guido, Terés, Lara Bianco, Gianotti, Luca, Baiocchi, Gian Luca, Sommacale, Daniele, and Romano, Fabrizio

Published
2021
Full Text
View/download PDF

9. Factors affecting overall survival and disease-free survival after surgery for hepatocellular carcinoma: a nomogram-based prognostic model—a Western European multicenter study

Author

Masuda, Yoshio, primary, Yeo, Mark Hao Xuan, additional, Burdio, Fernando, additional, Sanchez-Velazquez, Patricia, additional, Perez-Xaus, Marc, additional, Pelegrina, Amalia, additional, Koh, Ye Xin, additional, Di Martino, Marcello, additional, Goh, Brian K.P., additional, Tan, Ek Khoon, additional, Teo, Jin Yao, additional, Romano, Fabrizio, additional, Famularo, Simone, additional, Ferrari, Cecilia, additional, Griseri, Guido, additional, Piardi, Tullio, additional, Sommacale, Daniele, additional, Gianotti, Luca, additional, Molfino, Sarah, additional, Baiocchi, Gianluca, additional, and Ielpo, Benedetto, additional

Published
2023
Full Text
View/download PDF

10. Survival benefit of second line therapies for recurrent hepatocellular carcinoma: repeated hepatectomy, thermoablation and second-line transplant referral in a real life national scenario

Author

Famularo, Simone, primary, Cillo, Umberto, additional, Lauterio, Andrea, additional, Donadon, Matteo, additional, Vitale, Alessandro, additional, Serenari, Matteo, additional, Cipriani, Federica, additional, Fazio, Federico, additional, Giuffrida, Mario, additional, Ardito, Francesco, additional, Dominioni, Tommaso, additional, Garancini, Mattia, additional, Lai, Quirino, additional, Nicolini, Daniele, additional, Molfino, Sarah, additional, Perri, Pasquale, additional, Pinotti, Enrico, additional, Conci, Simone, additional, Ferrari, Cecilia, additional, Zanello, Matteo, additional, Patauner, Stefan, additional, Zimmitti, Giuseppe, additional, Germani, Paola, additional, Chiarelli, Marco, additional, Romano, Maurizio, additional, De Angelis, Michela, additional, La Barba, Giuliano, additional, Troci, Albert, additional, Ferraro, Valentina, additional, Izzo, Francesco, additional, Antonucci, Adelmo, additional, Belli, Andrea, additional, Memeo, Riccardo, additional, Crespi, Michele, additional, Ercolani, Giorgio, additional, Boccia, Luigi, additional, Zanus, Giacomo, additional, Tarchi, Paola, additional, Hilal, Moh'd Abu, additional, Frena, Antonio, additional, Jovine, Elio, additional, Griseri, Guido, additional, Ruzzenente, Andrea, additional, Zago, Mauro, additional, Grazi, Gianluca, additional, Baiocchi, Gian L., additional, Vivarelli, Marco, additional, Rossi, Massimo, additional, Romano, Fabrizio, additional, Maestri, Marcello, additional, Giuliante, Felice, additional, Valle, Raffaele D., additional, Ferrero, Alessandro, additional, Aldrighetti, Luca, additional, De Carlis, Luciano, additional, Cescon, Matteo, additional, Torzilli, Guido, additional, Milana, Flavio, additional, Bertacco, Alessandra, additional, De Carlis, Riccardo, additional, Ratti, Francesca, additional, Russolillo, Nadia, additional, Iaria, Maurizio, additional, Razionale, Francesco, additional, Tartaglia, Giuseppe, additional, Ciulli, Cristina, additional, Carissimi, Francesca, additional, Laureiro, Zoe L., additional, Marinelli, Laura, additional, DePeppo, Valerio, additional, Montuori, Mauro, additional, Marchitelli, Ivan, additional, Franceschi, Angelo, additional, Notte, Francesca, additional, Manzoni, Alberto, additional, Cosola, Davide, additional, Corleone, Pio, additional, Fumagalli, Luca, additional, Salvador, Luca, additional, Mantovani, Guido, additional, Cucchetti, Alessandro, additional, Cammarata, Francesco, additional, Conticchio, Maria, additional, Patrone, Renato, additional, and Bernasconi, Davide P., additional

Published
2023
Full Text
View/download PDF

11. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Ardito, Francesco, Carissimi, Francesca, Perri, Pasquale, Iaria, Maurizio, Dominioni, Tommaso, Zanello, Matteo, Conci, Simone, Molfino, Sarah, LaBarba, Giuliano, Ferrari, Cecilia, Germani, Paola, Patauner, Stefan, Pinotti, Enrico, Lodo, Enrico, Garatti, Marco, Sciannamea, Ivano, Troci, Albert, Conticchio, Maria, Floridi, Antonio, Chiarelli, Marco, Fumagalli, Luca, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Zimmitti, Giuseppe, Zanus, Giacomo, Zago, Mauro, Frena, Antonio, Tarchi, Paola, Griseri, Guido, Ercolani, Giorgio, Baiocchi, Gian Luca, Ruzzenente, Andrea, Jovine, Elio, Maestri, Marcello, DallaValle, Raffaele, Grazi, Gian Luca, Giuliante, Felice, Aldrighetti, Luca, Torzilli, Guido, and Romano, Fabrizio

Published
2020
Full Text
View/download PDF

12. The Impact of Hospital Volume on Failure to Rescue after Liver Resection for Hepatocellular Carcinoma: Analysis from the HE.RC.O.LE.S. Italian Registry

Author

Ardito, Francesco, Famularo, Simone, Aldrighetti, Luca, Grazi, Gian Luca, DallaValle, Raffaele, Maestri, Marcello, Jovine, Elio, Ruzzenente, Andrea, Baiocchi, Gian Luca, Ercolani, Giorgio, Griseri, Guido, Frena, Antonio, Zanus, Giacomo, Zimmitti, Giuseppe, Antonucci, Adelmo, Crespi, Michele, Memeo, Riccardo, Romano, Fabrizio, and Giuliante, Felice

Published
2020
Full Text
View/download PDF

13. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Ardito, Francesco, Carissimi, Francesca, Perri, Pasquale, Iaria, Maurizio, Dominioni, Tommaso, Zanello, Matteo, Conci, Simone, Molfino, Sarah, LaBarba, Giuliano, Ferrari, Cecilia, Germani, Paola, Patauner, Stefan, Pinotti, Enrico, Lodo, Enrico, Garatti, Marco, Sciannamea, Ivano, Troci, Albert, Conticchio, Maria, Floridi, Antonio, Chiarelli, Marco, Fumagalli, Luca, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Zimmitti, Giuseppe, Zanus, Giacomo, Zago, Mauro, Frena, Antonio, Tarchi, Paola, Griseri, Guido, Ercolani, Giorgio, Baiocchi, Gian Luca, Ruzzenente, Andrea, Jovine, Elio, Maestri, Marcello, DallaValle, Raffaele, Grazi, Gian Luca, Giuliante, Felice, Aldrighetti, Luca, Torzilli, Guido, and Romano, Fabrizio

Abstract

Liver surgery is the first line treatment for hepatocarcinoma. Hepatocarcinoma Recurrence on the Liver Study (HERCOLES) Group was established in 2018 with the goal to create a network of Italian centres sharing data and promoting scientific research on hepatocellular carcinoma (HCC) in the surgical field. This is the first national report that analyses the trends in surgical and oncological outcomes. Register data were collected by 22 Italian centres between 2008 and 2018. One hundred sixty-four variables were collected, regarding liver functional status, tumour burden, radiological, intraoperative and perioperative data, histological features and oncological follow-up. 2381 Patients were enrolled. Median age was 70 (IQR 63–75) years old. Cirrhosis was present in 1491 patients (62.6%), and Child-A were 89.9% of cases. HCC was staged as BCLC0-A in almost 50% of cases, while BCLC B and C were 20.7% and 17.9% respectively. Major liver resections were 481 (20.2%), and laparoscopy was employed in 753 (31.6%) cases. Severe complications occurred only in 5%. Postoperative ascites was recorded in 10.5% of patients, while posthepatectomy liver failure was observed in 4.9%. Ninety-day mortality was 2.5%. At 5 years, overall survival was 66.1% and disease-free survival was 40.9%. Recurrence was intrahepatic in 74.6% of cases. Redo-surgery and thermoablation for recurrence were performed up to 32% of cases. This is the most updated Italian report of the national experience in surgical treatment for HCC. This dataset is consistently allowing the participating centres in creating multicentric analysis which are already running with a very large sample size and strong power.

Published
2024
Full Text
View/download PDF

14. Single Large Hepatocellular Carcinoma > 5 cm with Surgical Indication: Is it Mandatory a Major Hepatectomy? A Propensity-score Weighted Analysis

Author

Garancini, M., primary, Ferrero, A., additional, De Carlis, L., additional, Grazi, G.L., additional, Giuliante, F., additional, Cillo, U., additional, Cescon, M., additional, Valle, R. Dalla, additional, Vivarelli, M., additional, Torzilli, G., additional, Aldrighetti, L., additional, Romano, Fabrizio, additional, Donadon, Matteo, additional, Cipriani, Federica, additional, Serenari, Matteo, additional, Ardito, Francesco, additional, Lauterio, Andrea, additional, Vitale, Alessandro, additional, Fazio, Federico, additional, Nicolini, Daniele, additional, Perri, Pasquale, additional, Iaria, Giuseppe, additional, Famularo, Simone, additional, Dominioni, Tommaso, additional, Zanello, Matteo, additional, Lai, Quirino, additional, Conci, Simone, additional, Molfino, Sarah, additional, Ferrari, Cecilia, additional, Germani, Paola, additional, Scotti, Mauro Alessandro, additional, Zago, Mauro, additional, Zimmitti, Giuseppe, additional, La Barba Maurizio Romano, Giuliano, additional, Sciannamea, Ivano, additional, Fumagalli, Luca, additional, Troci, Albert, additional, Ferraro, Valentina, additional, Memeo, Riccardo, additional, Crespi, Michele, additional, Chiarelli, Marco, additional, Antonucci, Adelmo, additional, Zanus, Giacomo, additional, Ercolani, Giorgio, additional, Hilal, Moh’d Abu, additional, Pinotti, Enrico, additional, Tarchi, Paola, additional, Griseri, Guido, additional, Baiocchi, Gian Luca, additional, Ruzzenente, Andrea, additional, Rossi, Massimo, additional, Jovine, Elio, additional, and Maestri, Marcello, additional

Published
2023
Full Text
View/download PDF

15. Hepatectomy Versus Sorafenib in Advanced Non-Metastatic Hepatocellular Carcinoma: A Real-Life Multicentric Weighted Comparison

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, Famularo, S, Donadon, M, Cipriani, F, Giuliante, F, Ferri, S, Celsa, C, Ferrero, A, Foschi, F, Baiocchi, G, Biasini, E, Campani, C, Valle, R, Pellizzaro, F, Baroni, G, Raimondo, G, Mega, A, Chiarelli, M, Maestri, M, Gasbarrini, A, Jovine, E, Grazi, G, Rapaccini, G, Ruzzenente, A, Morisco, F, Sacco, R, Memeo, R, Crespi, M, Antonucci, A, Bernasconi, D, Romano, F, Griseri, G, Aldrighetti, L, Torzilli, G, Trevisani, F, Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pelizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P, Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, Trevisani, Franco, and Pellizzaro, Filippo

Subjects
Niacinamide, Carcinoma, Hepatocellular, Hepatocellular carcinoma, hepatocellular carcinoma, surgery, sorafenib, bclc, Phenylurea Compounds, Carcinoma, Settore MED/09 - MEDICINA INTERNA, Liver Neoplasms, advanced HCC, Hepatocellular, Antineoplastic Agents, systemic therapies, Sorafenib, BCLC C, NO, Treatment Outcome, macrovascular invasion, Humans, Hepatectomy, Surgery, Neoplasm Staging, Retrospective Studies, Liver surgery
Abstract

Objective: The aim of the study was to compare SURG vs SOR regarding the OS and progression-free survival (PFS) in a real-world clinical scenario. Background data: The treatment for advanced nonmetastatic HCC belonging to the Barcelona Clinic Liver Cancer stage C (BCLC C) is still controversial. Methods: BCLC C patients without extrahepatic spread and tumoral invasion of the main portal trunk were considered. Surgical patients were obtained from the HE.RC.O.LE.S. Register, whereas sorafenib patients were obtained from the ITA.LI.CA register The inverse probability weighting (IPW) method was adopted to balance the confounders between the 2 groups. Results: Between 2008 and 2019, 478 patients were enrolled: 303 in SURG and 175 in SOR group. Eastern Cooperative Oncological Group Performance Status (ECOG-PS), presence of cirrhosis, steatosis, Child-Pugh grade, hepatitis B virus and hepatitis C virus, alcohol intake, collateral veins, bilobar disease, localization of the tumor thrombus, number of nodules, alpha-fetoprotein, age, and Charlson Comorbidity index were weighted by IPW to create two balanced pseudo-populations: SURG = 374 and SOR = 263. After IPW, 1-3-5 years OS was 83.6%, 68.1%, 55.9% for SURG, and 42.3%, 17.8%, 12.8% for SOR (P < 0.001). Similar trends were observed after subgrouping patients by ECOG-PS = 0 and ECOG-PS >0, and by the intrahepatic location of portal vein invasion. At Cox regression, sorafenib treatment (hazard ratio 4.436; 95% confidence interval 3.19-6.15; P < 0.001) and Charlson Index (hazard ratio 1.162; 95% confidence interval 1.06-1.27; P = 0.010) were the only independent predictors of mortality. PFS at 1-3-5 years were 65.9%, 40.3%, 24.3% for SURG and 21.6%, 3.5%, 2.9% for SOR (P = 0.007). Conclusions: In BCLC C patients without extrahepatic spread but with intrahepatic portal invasion, liver resection, if feasible, was followed by better OS and PFS compared with sorafenib.

Published
2022

16. The largest western experience on salvage hepatectomy for recurrent hepatocellular carcinoma: propensity score-matched analysis on behalf of He.RC.O.Le.Study Group

Author

Iaria, Maurizio, primary, Bianchi, Giorgio, additional, Fazio, Federico, additional, Ardito, Francesco, additional, Perri, Pasquale, additional, Pontarolo, Nicholas, additional, Conci, Simone, additional, Donadon, Matteo, additional, Zanello, Matteo, additional, Lai, Quirino, additional, Famularo, Simone, additional, Molfino, Sarah, additional, Sciannamea, Ivano, additional, Fumagalli, Luca, additional, Germani, Paola, additional, Floridi, Antonio, additional, Ferrari, Cecilia, additional, Zimmitti, Giuseppe, additional, Troci, Albert, additional, Zago, Mauro, additional, Ferraro, Valentina, additional, Cipriani, Federica, additional, Patauner, Stefan, additional, La Barba, Giuliano, additional, Romano, Maurizio, additional, Zanus, Giacomo, additional, Ercolani, Giorgio, additional, Frena, Antonio, additional, Aldrighetti, Luca, additional, Memeo, Riccardo, additional, Pinotti, Enrico, additional, Crespi, Michele, additional, Hilal, Moh'd Abu, additional, Griseri, Guido, additional, Tarchi, Paola, additional, Chiarelli, Marco, additional, Antonucci, Adelmo, additional, Baiocchi, Gian L., additional, Romano, Fabrizio, additional, Rossi, Massimo, additional, Jovine, Elio, additional, Torzilli, Guido, additional, Ruzzenente, Andrea, additional, Maestri, Marcello, additional, Grazi, Gian L., additional, Giuliante, Felice, additional, Ferrero, Alessandro, additional, Dalla Valle, Raffaele, additional, Giuffrida, Mario, additional, Russolillo, Nadia, additional, Razionale, Francesco, additional, De Peppo, Valerio, additional, Tomasoni, Matteo, additional, Marchitelli, Ivan, additional, Costa, Guido, additional, Laureiro, Zoe L., additional, Scotti, Mauro, additional, Calcagno, Pietro, additional, Cosola, Davide, additional, Franceschi, Angelo, additional, Manzoni, Alberto, additional, Pennacchi, Luca, additional, Montuori, Mauro, additional, Conticchio, Maria, additional, Ratti, Francesca, additional, Notte, Francesca, additional, Cucchetti, Alessandro, additional, Salvador, Luca, additional, Corleone, Pio, additional, Garancini, Mattia, additional, and Ciulli, Cristina, additional

Published
2022
Full Text
View/download PDF

18. The Impact of Postoperative Ascites on Survival After Surgery for Hepatocellular Carcinoma: a National Study

Author

Famularo, Simone, primary, Donadon, Matteo, additional, Cipriani, Federica, additional, Ardito, Francesco, additional, Iaria, Maurizio, additional, Carissimi, Francesca, additional, Perri, Pasquale, additional, Dominioni, Tommaso, additional, Zanello, Matteo, additional, Conci, Simone, additional, Molfino, Sarah, additional, D’Acapito, Fabrizio, additional, Germani, Paola, additional, Ferrari, Cecilia, additional, Patauner, Stefan, additional, Pinotti, Enrico, additional, Sciannamea, Ivano, additional, Garatti, Marco, additional, Lodo, Enrico, additional, Troci, Albert, additional, Delvecchio, Antonella, additional, Floridi, Antonio, additional, Bernasconi, Davide Paolo, additional, Fumagalli, Luca, additional, Chiarelli, Marco, additional, Memeo, Riccardo, additional, Crespi, Michele, additional, Zanus, Giacomo, additional, Zimmitti, Giuseppe, additional, Antonucci, Adelmo, additional, Zago, Mauro, additional, Frena, Antonio, additional, Griseri, Guido, additional, Tarchi, Paola, additional, Ercolani, Giorgio, additional, Baiocchi, Gian Luca, additional, Ruzzenente, Andrea, additional, Jovine, Elio, additional, Maestri, Marcello, additional, Grazi, GianLuca, additional, Valle, Raffaele Dalla, additional, Giuliante, Felice, additional, Aldrighetti, Luca, additional, Romano, Fabrizio, additional, Torzilli, Guido, additional, Costa, Guido, additional, Ciulli, Cristina, additional, Giani, Alessandro, additional, Ratti, Francesca, additional, Bellobono, Manuela, additional, Cremaschi, Elena, additional, Valsecchi, Maria Grazia, additional, De Peppo, Valerio, additional, Calabrese, Francesco, additional, DeSario, Giuseppina, additional, Lazzari, Giovanni, additional, Cucchetti, Alessandro, additional, Cosola, Davide, additional, Percivale, Andrea, additional, Ciola, Michele, additional, Montuori, Mauro, additional, Frassani, Silvia, additional, Manzoni, Alberto, additional, Salvador, Luca, additional, Pennacchi, Luca, additional, Corleone, Pio, additional, and Conticchio, Maria, additional

Published
2021
Full Text
View/download PDF

19. Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Fazio, Federico, Ardito, Francesco, Iaria, Maurizio, Perri, Pasquale, Conci, Simone, Dominioni, Tommaso, Lai, Quirino, La Barba, Giuliano, Patauner, Stefan, Molfino, Sarah, Germani, Paola, Zimmitti, Giuseppe, Pinotti, Enrico, Zanello, Matteo, Fumagalli, Luca, Ferrari, Cecilia, Romano, Maurizio, Delvecchio, Antonella, Valsecchi, Maria Grazia, Antonucci, Adelmo, Piscaglia, Fabio, Farinati, Fabio, Kawaguchi, Yoshikuni, Hasegawa, Kiyoshi, Memeo, Riccardo, Zanus, Giacomo, Griseri, Guido, Chiarelli, Marco, Jovine, Elio, Zago, Mauro, Abu Hilal, Moh’d, Tarchi, Paola, Baiocchi, Gian Luca, Frena, Antonio, Ercolani, Giorgio, Rossi, Massimo, Maestri, Marcello, Ruzzenente, Andrea, Grazi, Gian Luca, Dalla Valle, Raffaele, Romano, Fabrizio, Giuliante, Felice, Ferrero, Alessandro, Aldrighetti, Luca, Bernasconi, Davide P., and Torzilli, Guido

Abstract

IMPORTANCE: Clear indications on how to select retreatments for recurrent hepatocellular carcinoma (HCC) are still lacking. OBJECTIVE: To create a machine learning predictive model of survival after HCC recurrence to allocate patients to their best potential treatment. DESIGN, SETTING, AND PARTICIPANTS: Real-life data were obtained from an Italian registry of hepatocellular carcinoma between January 2008 and December 2019 after a median (IQR) follow-up of 27 (12-51) months. External validation was made on data derived by another Italian cohort and a Japanese cohort. Patients who experienced a recurrent HCC after a first surgical approach were included. Patients were profiled, and factors predicting survival after recurrence under different treatments that acted also as treatment effect modifiers were assessed. The model was then fitted individually to identify the best potential treatment. Analysis took place between January and April 2021. EXPOSURES: Patients were enrolled if treated by reoperative hepatectomy or thermoablation, chemoembolization, or sorafenib. MAIN OUTCOMES AND MEASURES: Survival after recurrence was the end point. RESULTS: A total of 701 patients with recurrent HCC were enrolled (mean [SD] age, 71 [9] years; 151 [21.5%] female). Of those, 293 patients (41.8%) received reoperative hepatectomy or thermoablation, 188 (26.8%) received sorafenib, and 220 (31.4%) received chemoembolization. Treatment, age, cirrhosis, number, size, and lobar localization of the recurrent nodules, extrahepatic spread, and time to recurrence were all treatment effect modifiers and survival after recurrence predictors. The area under the receiver operating characteristic curve of the predictive model was 78.5% (95% CI, 71.7%-85.3%) at 5 years after recurrence. According to the model, 611 patients (87.2%) would have benefited from reoperative hepatectomy or thermoablation, 37 (5.2%) from sorafenib, and 53 (7.6%) from chemoembolization in terms of potential survival after recurrence. Compared with patients for which the best potential treatment was reoperative hepatectomy or thermoablation, sorafenib and chemoembolization would be the best potential treatment for older patients (median [IQR] age, 78.5 [75.2-83.4] years, 77.02 [73.89-80.46] years, and 71.59 [64.76-76.06] years for sorafenib, chemoembolization, and reoperative hepatectomy or thermoablation, respectively), with a lower median (IQR) number of multiple recurrent nodules (1.00 [1.00-2.00] for sorafenib, 1.00 [1.00-2.00] for chemoembolization, and 2.00 [1.00-3.00] for reoperative hepatectomy or thermoablation). Extrahepatic recurrence was observed in 43.2% (n = 16) for sorafenib as the best potential treatment vs 14.6% (n = 89) for reoperative hepatectomy or thermoablation as the best potential treatment and 0% for chemoembolization as the best potential treatment. Those profiles were used to constitute a patient-tailored algorithm for the best potential treatment allocation. CONCLUSIONS AND RELEVANCE: The herein presented algorithm should help in allocating patients with recurrent HCC to the best potential treatment according to their specific characteristics in a treatment hierarchy fashion.

Published
2023
Full Text
View/download PDF

21. Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison

Author

Famularo, Simone, primary, Donadon, Matteo, additional, Cipriani, Federica, additional, Bernasconi, Davide P., additional, LaBarba, Giuliano, additional, Dominioni, Tommaso, additional, Iaria, Maurizio, additional, Molfino, Sarah, additional, Conci, Simone, additional, Ferrari, Cecilia, additional, Garatti, Marco, additional, Delvecchio, Antonella, additional, Troci, Albert, additional, Patauner, Stefan, additional, Frassani, Silvia, additional, Cosimelli, Maurizio, additional, Zanus, Giacomo, additional, Giuliante, Felice, additional, Jovine, Elio, additional, Valsecchi, Maria G., additional, Grazi, GianLuca, additional, Antonucci, Adelmo, additional, Frena, Antonio, additional, Crespi, Michele, additional, Memeo, Riccardo, additional, Zimmitti, Giuseppe, additional, Griseri, Guido, additional, Ruzzenente, Andrea, additional, Baiocchi, Gianluca, additional, DallaValle, Raffaele, additional, Maestri, Marcello, additional, Ercolani, Giorgio, additional, Aldrighetti, Luca, additional, Torzilli, Guido, additional, Romano, Fabrizio, additional, Ciulli, Cristina, additional, Giani, Alessandro, additional, Carissimi, Francesca, additional, Costa, Guido, additional, Ratti, Francesca, additional, Cucchetti, Alessandro, additional, Calabrese, Francesco, additional, Cremaschi, Elena, additional, Lazzari, Giovanni, additional, Franceschi, Angelo, additional, Sega, Valentina, additional, Conticchio, Maria, additional, Pennacchi, Luca, additional, Ciola, Michele, additional, Sciannamea, Ivano, additional, and De Peppo, Valerio, additional

Published
2021
Full Text
View/download PDF

23. Single Large Hepatocellular Carcinoma > 5 cm with Surgical Indication: Is it Mandatory a Major Hepatectomy? A Propensity-score Weighted Analysis

Author

Romano, Fabrizio, Donadon, Matteo, Cipriani, Federica, Serenari, Matteo, Ardito, Francesco, Lauterio, Andrea, Vitale, Alessandro, Fazio, Federico, Nicolini, Daniele, Perri, Pasquale, Iaria, Giuseppe, Famularo, Simone, Dominioni, Tommaso, Zanello, Matteo, Lai, Quirino, Conci, Simone, Molfino, Sarah, Ferrari, Cecilia, Germani, Paola, Scotti, Mauro Alessandro, Zago, Mauro, Zimmitti, Giuseppe, La Barba Maurizio Romano, Giuliano, Sciannamea, Ivano, Fumagalli, Luca, Troci, Albert, Ferraro, Valentina, Memeo, Riccardo, Crespi, Michele, Chiarelli, Marco, Antonucci, Adelmo, Zanus, Giacomo, Ercolani, Giorgio, Hilal, Moh’d Abu, Pinotti, Enrico, Tarchi, Paola, Griseri, Guido, Baiocchi, Gian Luca, Ruzzenente, Andrea, Rossi, Massimo, Jovine, Elio, Maestri, Marcello, Garancini, M., Ferrero, A., De Carlis, L., Grazi, G.L., Giuliante, F., Cillo, U., Cescon, M., Valle, R. Dalla, Vivarelli, M., Torzilli, G., and Aldrighetti, L.

Published
2023
Full Text
View/download PDF

24. Biliary Tree Cysts and Surgical Treatment: Outcomes in a Multicentric Study.

Author

Ferrari, Cecilia, Blanco Rodríguez, Manuel, Molina, Víctor, Martín, Belén, Espinet, Marina, Percivale, Andrea, Griseri, Guido, Moral, Antonio, and Sánchez-Cabús, Santiago

Subjects
BILIARY tract, CHOLANGITIS, CHOLANGIOGRAPHY, TREATMENT effectiveness, CYSTS (Pathology), WESTERN countries, ABDOMINAL pain, RESEARCH, BILE duct tumors, BILE duct abnormalities, RETROSPECTIVE studies, EVALUATION research, COMPARATIVE studies, BILE ducts, HEPATECTOMY, DISEASE complications
Abstract

Background: Biliary tree cysts (BTCs) represent an either localized or multifocal abnormal dilatation of the biliary tree, which entails an increased risk of acute cholangitis and cholangiocarcinoma (2.5%-16%). Its incidence in Western countries is ∼1/100.000-1/150.000, being more frequent in Asia (1/1.000). These cysts are usually classified according to Todani classification, which is based on site and morphology of cysts. Patients and Methods: This is a retrospective multicentric descriptive study of patients surgically treated for BTCs. From 2005 to 2018, 25 cases were collected between Hospital de la Santa Creu i Sant Pau (Barcelona, Spain) and Ospedale San Paolo (Savona, Italy). Clinical presentation was characterized by abdominal pain, jaundice, fever, and sometimes weight loss. Eight patients presented Todani type I, 1 patient Todani type II, 3 patients Todani III, 1 patient Todani type IV, and 12 patients Todani type V. Results: Among the 25 surgically treated patients, 12 patients underwent liver resection, 7 patients underwent resection of the extrahepatic biliary tree, 3 patients underwent BTC removal through a duodenotomy, 1 patient underwent resection of the extrahepatic biliary tree and liver resection, and 2 patients underwent pancreatoduodenectomy. Overall 30-day morbidity rate was 20%, and 90-day mortality was 0%. Pathologic examination confirmed diagnosis of cholangiocarcinoma in 5 patients (20%). After a median follow-up of 59 months, 20 patients are alive and in good conditions, whereas 50% of patients with cholangiocarcinoma died for disease progression. Conclusions: Surgical treatment for BTCs is associated with acceptable postoperative outcomes, with moderate morbidity and null mortality rates. Moreover, the risk of developing cholangiocarcinoma is still high that prompts surgical treatment once diagnosis is made. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Factors Affecting Local and Intra Hepatic Distant Recurrence After Surgery for Hcc: An Alternative Perspective on Microvascular Invasion and Satellitosis – A Western European Multicentre Study

Author

Famularo, Simone, primary, Piardi, Tullio, additional, Molfino, Sarah, additional, Di Martino, Marcello, additional, Ferrari, Cecilia, additional, Ielpo, Benedetto, additional, Diago, Maria Victoria, additional, Giani, Alessandro, additional, Griseri, Guido, additional, Terés, Lara Bianco, additional, Gianotti, Luca, additional, Baiocchi, Gian Luca, additional, Sommacale, Daniele, additional, and Romano, Fabrizio, additional

Published
2020
Full Text
View/download PDF

27. Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma

Author

Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Giuliante, Felice, Ferri, Silvia, Celsa, Ciro, Ferrero, Alessandro, Foschi, Francesco Giuseppe, Baiocchi, Gian Luca, Biasini, Elisabetta, Campani, Claudia, Valle, Raffaele Dalla, Pellizzaro, Filippo, Baroni, Gianluca Svegliati, Raimondo, Giovanni, Mega, Andrea, Chiarelli, Marco, Maestri, Marcello, Gasbarrini, Antonio, Jovine, Elio, Grazi, Gian Luca, Rapaccini, Gian Ludovico, Ruzzenente, Andrea, Morisco, Filomena, Sacco, Rodolfo, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Bernasconi, Davide P., Romano, Fabrizio, Griseri, Guido, Aldrighetti, Luca, Torzilli, Guido, and Trevisani, Franco

Published
2022
Full Text
View/download PDF

28. Correction to: Diffusion, outcomes and implementation of minimally invasive liver surgery: a snapshot from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry (Updates in Surgery, (2017), 69, 3, (271-283), 10.1007/s13304-017-0489-x)

Author

Aldrighetti, Luca, Ratti, Francesca, Cillo, Umberto, Ferrero, Alessandro, Ettorre, Giuseppe Maria, Guglielmi, Alfredo, Giuliante, Felice, Calise, Fulvio, Dalla Valle, Raffaele, Mazzaferro, Vincenzo, Jovine, Elio, De Carlis, Luciano Gregorio, Boggi, Ugo, Gruttadauria, Salvatore, Di Benedetto, Fabrizio, Reggiani, Paolo, Berti, Stefano, Ceccarelli, Graziano, Vincenti, Leonardo, Belli, Giulio, Torzilli, Guido, Zamboni, Fausto, Coratti, Andrea, Mezzatesta, Pietro, Santambrogio, Roberto, Navarra, Giuseppe, Giuliani, Antonio, Pinna, Antonio Daniele, Parisi, Amilcare, Colledan, Michele, Slim, Abdallah, Antonucci, Adelmo, Grazi, Gian Luca, Frena, Antonio, Sgroi, Giovanni, Brolese, Alberto, Morelli, Luca, Floridi, Antonio, Patriti, Alberto, Veneroni, Luigi, Ercolani, Giorgio, Boni, Luigi, Maida, Pietro, Griseri, Guido, Percivale, Andrea, Filauro, Marco, Guerriero, Silvio, Tisone, Giuseppe, Romito, Raffaele, Tedeschi, Umberto, Zimmitti, Giuseppe, Aldrighetti, L, Ratti, F, Cillo, U, Ferrero, A, Ettorre, G, Guglielmi, A, Giuliante, F, Calise, F, Dalla Valle, R, Mazzaferro, V, Jovine, E, De Carlis, L, Boggi, U, Gruttadauria, S, Di Benedetto, F, Reggiani, P, Berti, S, Ceccarelli, G, Vincenti, L, Belli, G, Torzilli, G, Zamboni, F, Coratti, A, Mezzatesta, P, Santambrogio, R, Navarra, G, Giuliani, A, Pinna, A, Parisi, A, Colledan, M, Slim, A, Antonucci, A, Grazi, G, Frena, A, Sgroi, G, Brolese, A, Morelli, L, Floridi, A, Patriti, A, Veneroni, L, Ercolani, G, Boni, L, Maida, P, Griseri, G, Percivale, A, Filauro, M, Guerriero, S, Tisone, G, Romito, R, Tedeschi, U, and Zimmitti, G

Subjects
Surgery, Settore MED/18
Abstract

A technical error led to incorrect rendering of the author group in this article. The correct authorship is as follows: Luca Aldrighetti, Francesca Ratti, Umberto Cillo, Alessandro Ferrero, Giuseppe Maria Ettorre, Alfredo Guglielmi, Felice Giuliante, Fulvio Calise on behalf of the Italian Group of Minimally Invasive Liver Surgery (I GO MILS) The collaborators are: Raffaele Dalla Valle, AOU Parma, Parma; Vincenzo Mazzaferro, Istituto Nazionale Tumori, Milano; Elio Jovine, Ospedale Maggiore, Bologna; Luciano Gregorio De Carlis, Ospedale Niguarda Ca’ Granda, Milano; Ugo Boggi, AOU Pisana, Pisa; Salvatore Gruttadauria, ISMETT, Palermo; Fabrizio Di Benedetto, AOU Policlinico di Modena, Modena; Paolo Reggiani, Ospedale Maggiore Policlinico, Milano; Stefano Berti, Ospedale Civile S.Andrea, La Spezia; Graziano Ceccarelli, Ospedale San Donato, Arezzo; Leonardo Vincenti, AOU Consorziale Policlinico, Bari; Giulio Belli, Ospedale SM Loreto Nuovo, Napoli; Guido Torzilli, Istituto Clinico Humanitas, Rozzano; Fausto Zamboni, Ospedale Brotzu, Cagliari; Andrea Coratti, AOU Careggi, Firenze; Pietro Mezzatesta, Casa di Cura La Maddalena, Palermo; Roberto Santambrogio, AO San Paolo, Milano; Giuseppe Navarra, AOU Policlinico G. Martino, Messina; Antonio Giuliani, AO R.N. Cardarelli, Napoli; Antonio Daniele Pinna, Policlinico Sant’Orsola Malpighi, Bologna; Amilcare Parisi, AO Santa Maria di Terni, Terni; Michele Colledan, AO Papa Giovanni XXIII, Bergamo; Abdallah Slim, AO Desio e Vimercate, Vimercate; Adelmo Antonucci, Policlinico di Monza, Monza; Gian Luca Grazi, Istituto Nazionale Tumori Regina Elena, Roma; Antonio Frena, Ospedale Centrale, Bolzano; Giovanni Sgroi, AO Treviglio-Caravaggio, Treviglio; Alberto Brolese, Ospedale S.Chiara, Trento; Luca Morelli, AOU Pisana, Pisa; Antonio Floridi, AO Ospedale Maggiore, Crema; Alberto Patriti, Ospedale San Matteo degli Infermi, Spoleto; Luigi Veneroni, Ospedale Infermi AUSL Romagna, Rimini; Giorgio Ercolani, Ospedale Morgagni Pierantoni, Forlì; Luigi Boni, AOU Fondazione Macchi, Varese; Pietro Maida, Ospedale Villa Betania, Napoli; Guido Griseri, Ospedale San Paolo, Savona; Andrea Percivale, Ospedale Santa Corona, Pietraligure; Marco Filauro, AO Galliera, Genova; Silvio Guerriero, Ospedale San Martino, Belluno; Giuseppe Tisone, Policlinico Tor Vergata, Roma; Raffaele Romito, AOU Maggiore della Carità, Novara; Umberto Tedeschi, AOU Integrata Verona, Verona; Giuseppe Zimmitti, Fondazione Poliambulanza, Brescia.

Published
2018

32. The Effect of a Liver Transplant Program on the Outcomes of Resectable Hepatocellular Carcinoma: A Nationwide Multicenter Analysis

Author

Serenari, M., Lenzi, J., Cucchetti, A., Cipriani, F., Donadon, M., Ardito, Francesco, Fazio, F., Nicolini, D., Iaria, M., Famularo, S., Perri, P., Ansaloni, L., Zanello, M., Lai, Q., Conci, S., Molfino, S., Ferrari, C., Germani, P., Zago, M., Romano, M., Zimmitti, G., Antonucci, A., Fumagalli, L., Troci, A., Ferraro, V., Memeo, R., Crespi, M., Chiarelli, M., Ercolani, G., Hilal, M. A., Zanus, G., Pinotti, E., Tarchi, P., Griseri, G., Baiocchi, G. L., Ruzzenente, A., Rossi, M., Jovine, E., Maestri, M., Grazi, G. L., Romano, F., Dalla Valle, R., Ravaioli, M., Vivarelli, M., Ferrero, A., Giuliante, Felice, Torzilli, G., Aldrighetti, L., Cescon, M., Gorgone, M., Ratti, F., Costa, G., Razionale, Francesco, Russolillo, N., Marinelli, Luca, Giuffrida, M., Scotti, M., Garancini, M., De Peppo, V., De Stefano, F., Laureiro, Z. L., Marchitelli, I., Franceschi, A., Cosola, D., Corleone, P., Montuori, M., Salvador, L., Manzoni, Annamaria, La Barba, G., Calcagno, P., Pennacchi, L., Conticchio, M., Serenari, Matteo, Lenzi, Jacopo, Cucchetti, Alessandro, Cipriani, Federica, Donadon, Matteo, Ardito, Francesco, Fazio, Federico, Nicolini, Daniele, Iaria, Maurizio, Famularo, Simone, Perri, Pasquale, Ansaloni, Luca, Zanello, Matteo, Lai, Quirino, Conci, Simone, Molfino, Sarah, Ferrari, Cecilia, Germani, Paola, Zago, Mauro, Romano, Maurizio, Zimmitti, Giuseppe, Antonucci, Adelmo, Fumagalli, Luca, Troci, Albert, Ferraro, Valentina, Memeo, Riccardo, Crespi, Michele, Chiarelli, Marco, Ercolani, Giorgio, Hilal, Mohamed Abu, Zanus, Giacomo, Pinotti, Enrico, Tarchi, Paola, Griseri, Guido, Baiocchi, Gian Luca, Ruzzenente, Andrea, Rossi, Massimo, Jovine, Elio, Maestri, Marcello, Grazi, Gian Luca, Romano, Fabrizio, Dalla Valle, Raffaele, Ravaioli, Matteo, Vivarelli, Marco, Ferrero, Alessandro, Giuliante, Felice, Torzilli, Guido, Aldrighetti, Luca, and Cescon, Matteo

Subjects
hepatectomy, complications, liver transplantation, salvage, Settore MED/18 - CHIRURGIA GENERALE, Surgery, hepatocellular carcinoma, case-mix
Abstract

To evaluate the effect of a liver transplantation (LT) program on the outcomes of resectable hepatocellular carcinoma (HCC).Surgical treatment of HCC includes both hepatic resection (HR) and LT. However, the presence of cirrhosis and the possibility of recurrence make the management of this disease complex and probably different according to the presence of a LT program.Patients undergoing HR for HCC between January 2005 and December 2019 were identified from a national database of HCC. The main study outcomes were major surgical complications according to the Comprehensive Complication Index (CCI), post-hepatectomy liver failure (PHLF), 90-day mortality, overall survival (OS), and disease-free survival (DFS). Secondary outcomes were salvage liver transplantation (SLT) and post-recurrence survival (PRS).A total of 3202 patients were included from 25 hospitals over the study period. Three out of 25 (12%) had a LT program. The presence of a LT program within a center was associated with a reduced probability of PHLF (OR=0.38) but not with OS and DFS. There was an increased probability of SLT when HR was performed in a transplant hospital (OR=12.05). Among transplant-eligible patients, those who underwent LT had a significantly longer PRS.This study showed that the presence of a LT program was associated with decreased PHLF rates and an increased probability to receive SLT in case of recurrence.

Published
2022

33. Curative versus palliative treatments for recurrent hepatocellular carcinoma: a multicentric weighted comparison

Author

Simone Famularo, Matteo Donadon, Federica Cipriani, Davide P. Bernasconi, Giuliano LaBarba, Tommaso Dominioni, Maurizio Iaria, Sarah Molfino, Simone Conci, Cecilia Ferrari, Marco Garatti, Antonella Delvecchio, Albert Troci, Stefan Patauner, Silvia Frassani, Maurizio Cosimelli, Giacomo Zanus, Felice Giuliante, Elio Jovine, Maria G. Valsecchi, GianLuca Grazi, Adelmo Antonucci, Antonio Frena, Michele Crespi, Riccardo Memeo, Giuseppe Zimmitti, Guido Griseri, Andrea Ruzzenente, Gianluca Baiocchi, Raffaele DallaValle, Marcello Maestri, Giorgio Ercolani, Luca Aldrighetti, Guido Torzilli, Fabrizio Romano, Cristina Ciulli, Alessandro Giani, Francesca Carissimi, Guido Costa, Francesca Ratti, Alessandro Cucchetti, Francesco Calabrese, Elena Cremaschi, Giovanni Lazzari, Angelo Franceschi, Valentina Sega, Maria Conticchio, Luca Pennacchi, Michele Ciola, Ivano Sciannamea, Valerio De Peppo, Famularo S., Donadon M., Cipriani F., Bernasconi D.P., LaBarba G., Dominioni T., Iaria M., Molfino S., Conci S., Ferrari C., Garatti M., Delvecchio A., Troci A., Patauner S., Frassani S., Cosimelli M., Zanus G., Giuliante F., Jovine E., Valsecchi M.G., Grazi G., Antonucci A., Frena A., Crespi M., Memeo R., Zimmitti G., Griseri G., Ruzzenente A., Baiocchi G., DallaValle R., Maestri M., Ercolani G., Aldrighetti L., Torzilli G., Romano F., Ciulli C., Giani A., Carissimi F., Costa G., Ratti F., Cucchetti A., Calabrese F., Cremaschi E., Lazzari G., Franceschi A., Sega V., Conticchio M., Pennacchi L., Ciola M., Sciannamea I., De Peppo V., Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Bernasconi, Davide P, Labarba, Giuliano, Dominioni, Tommaso, Iaria, Maurizio, Molfino, Sarah, Conci, Simone, Ferrari, Cecilia, Garatti, Marco, Delvecchio, Antonella, Troci, Albert, Patauner, Stefan, Frassani, Silvia, Cosimelli, Maurizio, Zanus, Giacomo, Giuliante, Felice, Jovine, Elio, Valsecchi, Maria G, Grazi, Gianluca, Antonucci, Adelmo, Frena, Antonio, Crespi, Michele, Memeo, Riccardo, Zimmitti, Giuseppe, Griseri, Guido, Ruzzenente, Andrea, Baiocchi, Gianluca, Dallavalle, Raffaele, Maestri, Marcello, Ercolani, Giorgio, Aldrighetti, Luca, Torzilli, Guido, and Romano, Fabrizio

Subjects
Sorafenib, medicine.medical_specialty, recurrence, Carcinoma, Hepatocellular, Tumor burden, 030230 surgery, liver, Gastroenterology, NO, 03 medical and health sciences, 0302 clinical medicine, hepatectomy, Retrospective Studie, Internal medicine, Humans, Medicine, Chemoembolization, Therapeutic, Liver surgery, Retrospective Studies, LS7_4, Hepatology, business.industry, Palliative Care, Liver Neoplasms, hepatocellular carcinoma, medicine.disease, Recurrent Hepatocellular Carcinoma, multicentric, Treatment Outcome, Time to recurrence, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Liver function, Neoplasm Recurrence, Local, business, medicine.drug, Human
Abstract

Background Management of recurrence after surgery for hepatocellular carcinoma (rHCC) is still a debate. The aim was to compare the Survival after Recurrence (SAR) of curative (surgery or thermoablation) versus palliative (TACE or Sorafenib) treatments for patients with rHCC. Methods This is a multicentric Italian study, which collected data between 2007 and 2018 from 16 centers. Selected patients were then divided according to treatment allocation in Curative (CUR) or Palliative (PAL) Group. Inverse Probability Weighting (IPW) was used to weight the groups. Results 1,560 patients were evaluated, of which 421 experienced recurrence and were then eligible: 156 in CUR group and 256 in PAL group. Tumor burden and liver function were weighted by IPW, and two pseudo-population were obtained (CUR = 397.5 and PAL = 415.38). SAR rates at 1, 3 and 5 years were respectively 98.3%, 76.7%, 63.8% for CUR and 91.7%, 64.2% and 48.9% for PAL (p = 0.007). Median DFS was 43 months (95%CI = 32-74) for CUR group, while it was 23 months (95%CI = 18-27) for PAL (p = 0.017). Being treated by palliative approach (HR = 1.75; 95%CI = 1.14–2.67; p = 0.01) and having a median size of the recurrent nodule>5 cm (HR = 1.875; 95%CI = 1.22–2.86; p = 0.004) were the only predictors of mortality after recurrence, while time to recurrence was the only protective factor (HR = 0.616; 95%CI = 0.54–0.69; p Conclusion Curative approaches may guarantee long-term survival in case of recurrence.

Published
2021

34. Hepatocellular carcinoma surgical and oncological trends in a national multicentric population: the HERCOLES experience

Author

Famularo, S., Donadon, M., Cipriani, Fabrizio, Ardito, Francesco, Carissimi, F., Perri, Pierluigi, Iaria, M., Dominioni, T., Zanello, M., Conci, S., Molfino, S., Labarba, G., Ferrari, C., Germani, P., Patauner, S., Pinotti, E., Lodo, E., Garatti, M., Sciannamea, I., Troci, A., Conticchio, M., Floridi, A., Chiarelli, M., Fumagalli, L., Memeo, R., Crespi, M., Antonucci, Anna Maria, Zimmitti, Giuseppe, Zanus, G., Zago, M., Frena, A., Tarchi, P., Griseri, G., Ercolani, G., Baiocchi, G. L., Ruzzenente, A., Jovine, E., Maestri, Marta, Dallavalle, R., Grazi, G. L., Giuliante, Felice, Aldrighetti, L., Torzilli, Guido, Romano, Federica, Bernasconi, D. P., Ciulli, C., Giani, A., Costa, G., Ratti, F., Bellobono, M., Calabrese, F., Cremaschi, E., De Peppo, V., Cucchetti, A., Lazzari, Giovanni, Percivale, A., Ciola, M., Sega, V., Frassani, S., Del Vecchio, Arianna, Pennacchi, L., Corleone, P., Cosola, D., Salvador, L., Montuori, M., Famularo, Simone, Donadon, Matteo, Cipriani, Federica, Ardito, Francesco, Carissimi, Francesca, Perri, Pasquale, Iaria, Maurizio, Dominioni, Tommaso, Zanello, Matteo, Conci, Simone, Molfino, Sarah, LaBarba, Giuliano, Ferrari, Cecilia, Germani, Paola, Patauner, Stefan, Pinotti, Enrico, Lodo, Enrico, Garatti, Marco, Sciannamea, Ivano, Troci, Albert, Conticchio, Maria, Floridi, Antonio, Chiarelli, Marco, Fumagalli, Luca, Memeo, Riccardo, Crespi, Michele, Antonucci, Adelmo, Zimmitti, Giuseppe, Zanus, Giacomo, Zago, Mauro, Frena, Antonio, Tarchi, Paola, Griseri, Guido, Ercolani, Giorgio, Baiocchi, Gian Luca, Ruzzenente, Andrea, Jovine, Elio, Maestri, Marcello, DallaValle, Raffaele, Grazi, Gian Luca, Giuliante, Felice, Aldrighetti, Luca, Torzilli, Guido, Romano, Fabrizio, Famularo, S., Donadon, M., Cipriani, F., Ardito, F., Carissimi, F., Perri, P., Iaria, M., Dominioni, T., Zanello, M., Conci, S., Molfino, S., Labarba, G., Ferrari, C., Germani, P., Patauner, S., Pinotti, E., Lodo, E., Garatti, M., Sciannamea, I., Troci, A., Conticchio, M., Floridi, A., Chiarelli, M., Fumagalli, L., Memeo, R., Crespi, M., Antonucci, A., Zimmitti, G., Zanus, G., Zago, M., Frena, A., Tarchi, P., Griseri, G., Ercolani, G., Baiocchi, G. L., Ruzzenente, A., Jovine, E., Maestri, M., Dallavalle, R., Grazi, G. L., Giuliante, F., Aldrighetti, L., Torzilli, G., Romano, F., Bernasconi, D. P., Ciulli, C., Giani, A., Costa, G., Ratti, F., Bellobono, M., Calabrese, F., Cremaschi, E., De Peppo, V., Cucchetti, A., Lazzari, G., Percivale, A., Ciola, M., Sega, V., Frassani, S., Del Vecchio, A., Pennacchi, L., Corleone, P., Cosola, D., Salvador, L., and Montuori, M.

Subjects
Male, Cirrhosis, Outcome Assessment, Hepatocellular carcinoma, Settore MED/18 - CHIRURGIA GENERALE, Datasets as Topic, HERCOLES, Hepatocarcinoma recurrence, Liver surgery, Redo surgery, Outcome Assessment, Health Care, Ascites, Registries, Laparoscopy, education.field_of_study, medicine.diagnostic_test, Liver Neoplasms, Middle Aged, Italy, Local, Radiological weapon, Female, medicine.symptom, Reoperation, medicine.medical_specialty, Carcinoma, Hepatocellular, Population, NO, Internal medicine, medicine, Hepatectomy, Humans, education, LS7_4, Aged, business.industry, Carcinoma, Hepatocellular, Perioperative, Hepatology, medicine.disease, Surgery, Health Care, Neoplasm Recurrence, Neoplasm Recurrence, Local, business
Abstract

Liver surgery is the first line treatment for hepatocarcinoma. Hepatocarcinoma Recurrence on the Liver Study (HERCOLES) Group was established in 2018 with the goal to create a network of Italian centres sharing data and promoting scientific research on hepatocellular carcinoma (HCC) in the surgical field. This is the first national report that analyses the trends in surgical and oncological outcomes. Register data were collected by 22 Italian centres between 2008 and 2018. One hundred sixty-four variables were collected, regarding liver functional status, tumour burden, radiological, intraoperative and perioperative data, histological features and oncological follow-up. 2381 Patients were enrolled. Median age was 70 (IQR 63-75) years old. Cirrhosis was present in 1491 patients (62.6%), and Child-A were 89.9% of cases. HCC was staged as BCLC0-A in almost 50% of cases, while BCLC B and C were 20.7% and 17.9% respectively. Major liver resections were 481 (20.2%), and laparoscopy was employed in 753 (31.6%) cases. Severe complications occurred only in 5%. Postoperative ascites was recorded in 10.5% of patients, while posthepatectomy liver failure was observed in 4.9%. Ninety-day mortality was 2.5%. At 5years, overall survival was 66.1% and disease-free survival was 40.9%. Recurrence was intrahepatic in 74.6% of cases. Redo-surgery and thermoablation for recurrence were performed up to 32% of cases. This is the most updated Italian report of the national experience in surgical treatment for HCC. This dataset is consistently allowing the participating centres in creating multicentric analysis which are already running with a very large sample size and strong power. Liver surgery is the first line treatment for hepatocarcinoma. Hepatocarcinoma Recurrence on the Liver Study (HERCOLES) Group was established in 2018 with the goal to create a network of Italian centres sharing data and promoting scientific research on hepatocellular carcinoma (HCC) in the surgical field. This is the first national report that analyses the trends in surgical and oncological outcomes. Register data were collected by 22 Italian centres between 2008 and 2018. One hundred sixty-four variables were collected, regarding liver functional status, tumour burden, radiological, intraoperative and perioperative data, histological features and oncological follow-up. 2381 Patients were enrolled. Median age was 70 (IQR 63–75) years old. Cirrhosis was present in 1491 patients (62.6%), and Child-A were 89.9% of cases. HCC was staged as BCLC0-A in almost 50% of cases, while BCLC B and C were 20.7% and 17.9% respectively. Major liver resections were 481 (20.2%), and laparoscopy was employed in 753 (31.6%) cases. Severe complications occurred only in 5%. Postoperative ascites was recorded in 10.5% of patients, while posthepatectomy liver failure was observed in 4.9%. Ninety-day mortality was 2.5%. At 5years, overall survival was 66.1% and disease-free survival was 40.9%. Recurrence was intrahepatic in 74.6% of cases. Redo-surgery and thermoablation for recurrence were performed up to 32% of cases. This is the most updated Italian report of the national experience in surgical treatment for HCC. This dataset is consistently allowing the participating centres in creating multicentric analysis which are already running with a very large sample size and strong power.

Published
2020

35. Single large hepatocellular carcinoma > 5 cm with surgical indication: is it mandatory a major hepatectomy? a propensity-score weighted analysis.

Author

Garancini M, Serenari M, Famularo S, Cipriani F, Ardito F, Russolillo N, Conci S, Nicolini D, Perri P, Zanello M, Iaria M, Lai Q, Romano M, La Barba G, Molfino S, Germani P, Dominioni T, Zimmiti G, Conticchio M, Fumagalli L, Zago M, Troci A, Sciannamea I, Ferrari C, Scotti MA, Griseri G, Antonucci A, Crespi M, Pinotti E, Chiarelli M, Memeo R, Hilal MA, Maestri M, Tarchi P, Baiocchi G, Ercolani G, Zanus G, Rossi M, Valle RD, Jovine E, Frena A, Patauner S, Grazi GL, Vivarelli M, Ruzzenente A, Ferrero A, Giuliante F, Aldrighetti L, Torzilli G, Cescon M, Bernasconi D, and Romano F

Subjects
Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Postoperative Complications etiology, Treatment Outcome, Survival Rate, Adult, Hepatectomy methods, Carcinoma, Hepatocellular surgery, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular mortality, Liver Neoplasms surgery, Liver Neoplasms pathology, Liver Neoplasms mortality, Propensity Score
Abstract

Purpose: Single large hepatocellular carcinoma >5cm (SLHCC) traditionally requires a major liver resection. Minor resections are often performed with the goal to reduce morbidity and mortality. Aim of the study was to establish if a major resection should be considered the best treatment for SLHCC or a more limited resection should be preferred., Methods: A multicenter retrospective analysis of the HE.RC.O.LE.S. Group register was performed. All collected patients with surgically treated SLHCC were divided in 5 groups of treatment (major hepatectomy, sectorectomy, left lateral sectionectomy, segmentectomy, non-anatomical resection) and compared for baseline characteristics, short and long-term results. A propensity-score weighted analysis was performed., Results: 535 patients were enrolled in the study. Major resection was associated with significantly increased major complications compared to left lateral sectionanectomy, segmentectomy and non-anatomical resection (all p<0.05) and borderline significant increased major complications compared to sectorectomy (p=0.08). Left lateral sectionectomy showed better overall survival compared to major resection (p=0.02), while other groups of treatment resulted similar to major hepatectomy group for the same item. Absence of oncological benefit after major resection and similar outcomes among the 5 groups of treatment was confirmed even in the sub-population excluding patients with macrovascular invasion., Conclusion: Major resection was associated to increased major post-operative morbidity without long-term survival benefit; when technically feasible and oncologically adequate, minor resections should be preferred for the surgical treatment of SLHCC., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results